Related Experiment Video
Updated: Aug 6, 2026

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
Published on: June 21, 2024
Cyclic vomiting syndrome plus
Richard G Boles1, Amy L R Powers, Kathleen Adams
1Division of Medical Genetics, Childrens Hospital Los Angeles, Los Angeles, CA 90027, USA. rboles@chla.usc.edu
Insights
Cyclic vomiting syndrome with neuromuscular disease (CVS plus) presents a distinct phenotype. It shows earlier onset and increased comorbidities, possibly linked to mitochondrial dysfunction.
Area of Science:
- Neurology
- Genetics
- Pediatrics
Background:
- Cyclic vomiting syndrome (CVS) is a disabling childhood condition with episodes of nausea and vomiting.
- A subset of CVS patients (25%) exhibit coexisting neuromuscular disease, termed CVS plus.
- The distinctiveness of CVS plus within the broader CVS spectrum requires investigation.
Purpose of the Study:
- To determine if CVS patients with neuromuscular disease (CVS plus) represent a distinct subentity.
- To compare clinical characteristics between CVS plus and CVS without neuromuscular disease (CVS minus).
Main Methods:
- A clinical interview was conducted with 80 CVS sufferers from a disease association database.
- Subjects were categorized into CVS plus (≥2 neuromuscular manifestations) and CVS minus (0 manifestations).
- Neuromuscular disease manifestations were assessed, including cognitive, skeletal, cranial nerve, and seizure disorders.
Main Results:
- Neuromuscular disease manifestations clustered together in subjects.
- CVS plus patients had an earlier age of onset for vomiting episodes.
- CVS plus showed a 3-8 fold increased prevalence of dysautonomia and constitutional disorders, but similar sibling recurrence of neuromuscular disease.
Conclusions:
- CVS plus represents a distinct phenotypic entity, not necessarily genetically distinct from CVS minus.
- CVS plus predicts earlier disease onset and increased comorbidity with specific medical conditions.
- Mitochondrial dysfunction may underlie the distinct phenotype observed in CVS plus.
Abstract:
Cyclic vomiting syndrome, which is characterized by severe discrete episodes of nausea, vomiting, and lethargy, is a fairly common, disabling, predominately childhood condition. Approximately 25% of cases have coexisting neuromuscular disease manifestations (cyclic vomiting syndrome plus). To determine whether patients with cyclic vomiting syndrome and neuromuscular disease represent a distinct subentity within cyclic vomiting syndrome, a clinical interview was conducted regarding 80 randomly ascertained sufferers of cyclic vomiting syndrome from a disease association database. Cyclic vomiting syndrome plus and "cyclic vomiting syndrome minus," herein defined as the presence of at least two and zero neuromuscular disease manifestations, were present in 23 and 44 subjects, respectively. Neuromuscular disease manifestations, including cognitive disorders, skeletal myopathy, cranial nerve dysfunction, and seizure disorders, were found to statistically cluster together among the same subjects. In addition, subjects with cyclic vomiting syndrome with neuromuscular disease had an earlier age at onset for vomiting episodes and a three- to eightfold statistically increased prevalence for certain dysautonomia-related (migraine, chronic fatigue, neurovascular dystrophy) and constitutional (growth retardation and birth defects) disorders. However, subjects with cyclic vomiting syndrome with and without neuromuscular disease were equally likely to have a sibling affected with neuromuscular disease manifestations. We conclude that cyclic vomiting syndrome plus, although likely not genetically distinct from cyclic vomiting syndrome minus, represents a distinct phenotypic entity that predicts an earlier onset of disease and increased comorbidity with a distinct list of medical conditions, possibly owing to a higher degree of mitochondrial dysfunction.
Related Concept Videos
Pathophysiology of Vomiting
Pyloric Obstruction
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Gastrointestinal Motility Disorders
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

